
    
      This is a multisite, open-label, prospective and registered study designed to evaluate the
      efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic
      syndrome(PNS). The study will be Planned at 1500 participants, and subjects will be on study
      for up to one year. Data will be collected by authorized physicians for 48 weeks. all of the
      data included demographic characteristics, information about PNS, laboratory tests and
      adverse events.
    
  